Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns

Authors: Francesca Falasca, Daniele Di Carlo, Corrado De Vito, Isabella Bon, Gabriella d’Ettorre, Alessandra Fantauzzi, Ivano Mezzaroma, Caterina Fimiani, Maria Carla Re, Vincenzo Vullo, Guido Antonelli, Ombretta Turriziani

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Persistent residual viremia (RV) and low grade inflammation and immune activation have been associated with non-AIDS defining events. The impact of persistent RV and HIV-DNA load on immune activation/inflammation remains unclear. The purpose of this study was to gain new insights into the relation between viremia, markers of inflammation and HIV-DNA levels.

Methods

Three hundred and twenty-one HIV-infected patients were studied. A retrospective analysis of viremia values, prospectively collected for 48 months, was performed. Patients were separated into three groups: 113 TND (Target Not Detected, patients with sustained undetectable viremia); 113 RV (Residual Viremia, patients who had at least three detectable viral load (VL) values <37 copies/ml); 95 LLV (Low Level Viremia, patients with at least two VL values >37 but <200 copies/ml). HIV-DNA, TNF-α, IL-6 and sCD14 were analyzed.

Results

HIV-DNA, sCD14 and TNF-α were significantly lower in the TND group than in the RV and LLV groups. In addition, RV patients showed lower levels of HIV-DNA and sCD14 than LLV individuals. HIV-DNA load was not related to markers of inflammation. The ordinal logistic analysis showed that two independent variables were significantly associated with VL pattern: sCD14, HIV-DNA. In addition NRTIs plus NNRTIs and NRTIs plus PIs were negatively associated to VL pattern compared to INI-containing regimen.

Conclusions

Persistent undetectable viremia was associated with lower levels of inflammatory markers and HIV-DNA. However, the lack of normalization of these biomarkers in the TND group and the fact that HIV-DNA load was not associated with inflammation strongly suggest that other mechanisms play a major role in maintaining inflammation over time.
Literature
1.
go back to reference Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55:316–22.CrossRefPubMedPubMedCentral Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55:316–22.CrossRefPubMedPubMedCentral
3.
5.
go back to reference Erlandson KM, Campbell TB. Inflammation in chronic HIV infection: what can we do? J Infect Dis. 2015;212:339–42.CrossRefPubMed Erlandson KM, Campbell TB. Inflammation in chronic HIV infection: what can we do? J Infect Dis. 2015;212:339–42.CrossRefPubMed
6.
go back to reference Nasi M, De Biasi S, Gibellini L. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol. 2016;187:44–52.CrossRefPubMed Nasi M, De Biasi S, Gibellini L. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol. 2016;187:44–52.CrossRefPubMed
7.
go back to reference Margolick JB, Bream JH, Martínez-Maza O, Lopez J, Li X, Phair JP, et al. Frailty and circulating markers of inflammation in HIV+ and HIV- men in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2017;74:407–17.CrossRefPubMed Margolick JB, Bream JH, Martínez-Maza O, Lopez J, Li X, Phair JP, et al. Frailty and circulating markers of inflammation in HIV+ and HIV- men in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2017;74:407–17.CrossRefPubMed
8.
go back to reference Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 2013;21:6–13.CrossRefPubMed Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 2013;21:6–13.CrossRefPubMed
9.
go back to reference Dinh DM, Volpe GE, Duffalo C, Bhalchandra S, Tai AK, Kane AV, et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis. 2015;211:19–27.CrossRefPubMed Dinh DM, Volpe GE, Duffalo C, Bhalchandra S, Tai AK, Kane AV, et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis. 2015;211:19–27.CrossRefPubMed
10.
go back to reference Mavigner M, Delobel P, Cazabat M, Dubois M, L'faqihi-Olive FE, Raymond S, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One. 2009;4:e7658.CrossRefPubMedPubMedCentral Mavigner M, Delobel P, Cazabat M, Dubois M, L'faqihi-Olive FE, Raymond S, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One. 2009;4:e7658.CrossRefPubMedPubMedCentral
11.
go back to reference Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012;55:126–36.CrossRefPubMedPubMedCentral Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012;55:126–36.CrossRefPubMedPubMedCentral
12.
go back to reference Bastard JP, Soulié C, Fellahi S, Haïm-Boukobza S, Simon A, Katlama C, et al. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther. 2012;17:915–9.CrossRefPubMed Bastard JP, Soulié C, Fellahi S, Haïm-Boukobza S, Simon A, Katlama C, et al. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients. Antivir Ther. 2012;17:915–9.CrossRefPubMed
13.
go back to reference Borges ÁH, Silverberg MJ, Wentworth D, Grulich AE, Fätkenheuer G, Mitsuyasu R, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 2013;27:1433–41.CrossRefPubMedPubMedCentral Borges ÁH, Silverberg MJ, Wentworth D, Grulich AE, Fätkenheuer G, Mitsuyasu R, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 2013;27:1433–41.CrossRefPubMedPubMedCentral
14.
go back to reference Borges ÁH, O'Connor JL, Phillips AN, Neaton JD, Grund B, Neuhaus J, et al. Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-reactive protein or D-dimer during HIV infection. J Infect Dis. 2016;214:408–16.CrossRefPubMedPubMedCentral Borges ÁH, O'Connor JL, Phillips AN, Neaton JD, Grund B, Neuhaus J, et al. Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-reactive protein or D-dimer during HIV infection. J Infect Dis. 2016;214:408–16.CrossRefPubMedPubMedCentral
15.
go back to reference Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS One. 2016;11 doi:10.1371/journal.pone.0155100. Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS One. 2016;11 doi:10.​1371/​journal.​pone.​0155100.
17.
go back to reference Marchetti G, Cozzi-Lepri A, Merlini E, Bellistrì GM, Castagna A, Galli M, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS. 2011;25:1385–94.CrossRefPubMed Marchetti G, Cozzi-Lepri A, Merlini E, Bellistrì GM, Castagna A, Galli M, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS. 2011;25:1385–94.CrossRefPubMed
18.
19.
go back to reference Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29:463–71.CrossRefPubMedPubMedCentral Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29:463–71.CrossRefPubMedPubMedCentral
20.
go back to reference Reus S, Portilla J, Sánchez-Payá J, Francés R, Such J, Boix V, et al. Low-level HIV viremia is associated with microbial translocation and inflammation. J Acquir Immune Defic Syndr. 2013;62:129–34.CrossRefPubMed Reus S, Portilla J, Sánchez-Payá J, Francés R, Such J, Boix V, et al. Low-level HIV viremia is associated with microbial translocation and inflammation. J Acquir Immune Defic Syndr. 2013;62:129–34.CrossRefPubMed
21.
go back to reference Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2011;204:135–8.CrossRefPubMedPubMedCentral Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis. 2011;204:135–8.CrossRefPubMedPubMedCentral
22.
go back to reference Mexas AM, Graf EH, Pace MJ. Yu JJ, Papasavvas E, Azzoni L, et al. Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS 2012;26:2295–2306. Mexas AM, Graf EH, Pace MJ. Yu JJ, Papasavvas E, Azzoni L, et al. Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS 2012;26:2295–2306.
23.
go back to reference Falasca F, Mazzuti L, D’Ettorre G, Paoletti F, Tripolino O, Serafino S, et al. Dynamics of HIV DNA and residual viremia in patients treated with a raltegravir-containing regimen. J Acquir Immune Defic Syndr. 2015;68:e18–20.CrossRefPubMed Falasca F, Mazzuti L, D’Ettorre G, Paoletti F, Tripolino O, Serafino S, et al. Dynamics of HIV DNA and residual viremia in patients treated with a raltegravir-containing regimen. J Acquir Immune Defic Syndr. 2015;68:e18–20.CrossRefPubMed
24.
go back to reference Poizot-Martin I, Faucher O, Obry-Roguet V, Nicolino-Brunet C, Ronot-Bregigeon S, Dignat-George F, et al. Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years. J Clin Virol. 2013;57:351–5.CrossRefPubMed Poizot-Martin I, Faucher O, Obry-Roguet V, Nicolino-Brunet C, Ronot-Bregigeon S, Dignat-George F, et al. Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years. J Clin Virol. 2013;57:351–5.CrossRefPubMed
25.
go back to reference Allavena C, Rodallec A, Sécher S, Reliquet V, Baffoin S, André-Garnier E, et al. Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen. J Med Virol. 2013;85:1878–82.CrossRefPubMed Allavena C, Rodallec A, Sécher S, Reliquet V, Baffoin S, André-Garnier E, et al. Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen. J Med Virol. 2013;85:1878–82.CrossRefPubMed
26.
go back to reference Guihot A, Dentone C, Assoumou L, Parizot C, Calin R, Seang S, et al. Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. AIDS. 2016;30:327–30.CrossRefPubMed Guihot A, Dentone C, Assoumou L, Parizot C, Calin R, Seang S, et al. Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. AIDS. 2016;30:327–30.CrossRefPubMed
27.
go back to reference Méndez-Lagares G, Romero-Sánchez MC, Ruiz-Mateos E, Genebat M, Ferrando-Martínez S, Muñoz-Fernández MÁ, et al. Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. J Infect Dis. 2013;207:1221–5.CrossRefPubMed Méndez-Lagares G, Romero-Sánchez MC, Ruiz-Mateos E, Genebat M, Ferrando-Martínez S, Muñoz-Fernández MÁ, et al. Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14. J Infect Dis. 2013;207:1221–5.CrossRefPubMed
28.
go back to reference Mudd JC, Brenchley JM. Gut mucosal barrier dysfunction, microbial dysbiosis, and their role in HIV-1 disease progression. J Infect Dis. 2016;214:S58–66.CrossRefPubMed Mudd JC, Brenchley JM. Gut mucosal barrier dysfunction, microbial dysbiosis, and their role in HIV-1 disease progression. J Infect Dis. 2016;214:S58–66.CrossRefPubMed
29.
go back to reference Hel Z, Xu J, Denning WL, Helton ES, Huijbregts RP, Heath SL, et al. Dysregulation of systemic and mucosal humoral responses to microbial and food antigens as a factor contributing to microbial translocation and chronic inflammation in HIV-1 infection. PLoS Pathog. 2017; doi:10.1371/journal.ppat.1006087. Hel Z, Xu J, Denning WL, Helton ES, Huijbregts RP, Heath SL, et al. Dysregulation of systemic and mucosal humoral responses to microbial and food antigens as a factor contributing to microbial translocation and chronic inflammation in HIV-1 infection. PLoS Pathog. 2017; doi:10.​1371/​journal.​ppat.​1006087.
30.
go back to reference Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788–95.CrossRefPubMedPubMedCentral Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788–95.CrossRefPubMedPubMedCentral
31.
32.
go back to reference Borges ÁH, O'Connor JL, Phillips AN, Rönsholt FF, Pett S, Vjecha MJ, et al. Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis. 2015;212:585–95.CrossRefPubMedPubMedCentral Borges ÁH, O'Connor JL, Phillips AN, Rönsholt FF, Pett S, Vjecha MJ, et al. Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis. 2015;212:585–95.CrossRefPubMedPubMedCentral
33.
go back to reference Weiss L, Chevalier MF, Assoumou L, Didier C, Girard PM, Piketty C, et al. T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection. AIDS. 2014;28:1683–7.CrossRefPubMed Weiss L, Chevalier MF, Assoumou L, Didier C, Girard PM, Piketty C, et al. T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection. AIDS. 2014;28:1683–7.CrossRefPubMed
34.
go back to reference Wiesmann F, Braun P, Knickmann M, Knechten H. Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens. J Int AIDS Soc. 2014;17:19828.CrossRefPubMedPubMedCentral Wiesmann F, Braun P, Knickmann M, Knechten H. Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens. J Int AIDS Soc. 2014;17:19828.CrossRefPubMedPubMedCentral
35.
go back to reference Navarro J, Caballero E, Curran A, Burgos J, Ocaña I, Falcó V, et al. Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment. Antivir Ther. 2016;21:345–52.CrossRefPubMed Navarro J, Caballero E, Curran A, Burgos J, Ocaña I, Falcó V, et al. Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment. Antivir Ther. 2016;21:345–52.CrossRefPubMed
36.
go back to reference French MA, Cozzi-Lepri A, Arduino RC, Johnson M, Achhra AC, Landay A, et al. Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. AIDS. 2015;29:847–51.CrossRefPubMedPubMedCentral French MA, Cozzi-Lepri A, Arduino RC, Johnson M, Achhra AC, Landay A, et al. Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. AIDS. 2015;29:847–51.CrossRefPubMedPubMedCentral
37.
go back to reference Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780–90.CrossRefPubMedPubMedCentral Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780–90.CrossRefPubMedPubMedCentral
38.
go back to reference Krastinova E, Lecuroux C, Leroy C, Seng R, Cabie A, Rami A, et al. High soluble CD14 levels at primary HIV-1 infection predict more rapid disease progression. J Infect Dis. 2015;212:909–13.CrossRefPubMed Krastinova E, Lecuroux C, Leroy C, Seng R, Cabie A, Rami A, et al. High soluble CD14 levels at primary HIV-1 infection predict more rapid disease progression. J Infect Dis. 2015;212:909–13.CrossRefPubMed
39.
go back to reference Vaidya SA, Korner C, Sirignano MN, Amero M, Bazner S, Rychert J, et al. Tumor necrosis factor alpha is associated with viral control and early disease progression in patients with HIV type 1 infection. J Infect Dis. 2014;210:1042–6.CrossRefPubMedPubMedCentral Vaidya SA, Korner C, Sirignano MN, Amero M, Bazner S, Rychert J, et al. Tumor necrosis factor alpha is associated with viral control and early disease progression in patients with HIV type 1 infection. J Infect Dis. 2014;210:1042–6.CrossRefPubMedPubMedCentral
40.
go back to reference Hsu DC, Ma YF, Hur S, Li D, Rupert A, Scherzer R, et al. Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy. AIDS. 2016;30:2065–74.CrossRefPubMed Hsu DC, Ma YF, Hur S, Li D, Rupert A, Scherzer R, et al. Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy. AIDS. 2016;30:2065–74.CrossRefPubMed
Metadata
Title
Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns
Authors
Francesca Falasca
Daniele Di Carlo
Corrado De Vito
Isabella Bon
Gabriella d’Ettorre
Alessandra Fantauzzi
Ivano Mezzaroma
Caterina Fimiani
Maria Carla Re
Vincenzo Vullo
Guido Antonelli
Ombretta Turriziani
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2676-2

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue